usp33 Antibody

What is USP33 and why is it important in cellular research?

USP33, also known as ubiquitin specific peptidase 33 or VHL-interacting deubiquitinating enzyme 1, is a 942 amino acid protein that functions as a deubiquitinating enzyme within the ubiquitin-proteasome system. USP33 removes ubiquitin moieties from target proteins, preventing their degradation by the proteasome, which is essential for regulating protein degradation and maintaining cellular homeostasis . The protein is primarily located in the cytoplasm and nucleus, where it plays vital roles in signal transduction, transcriptional regulation, and cell cycle progression . USP33's interaction with the von Hippel-Lindau (VHL) protein, which regulates hypoxia-inducible factors, underscores its importance in cellular responses to oxygen levels . Additionally, USP33 has been implicated in cancer progression, particularly pancreatic cancer, making it an important target for cancer research .

What types of USP33 antibodies are available for research?

Several types of USP33 antibodies are available for research purposes. The USP33 Antibody (1D7) is a mouse monoclonal IgG1 kappa light chain antibody that specifically detects human USP33 protein . Commercial antibodies are available in various formats, including non-conjugated forms . Both monoclonal antibodies (like the 1D7 clone from Sigma) and polyclonal antibodies (available from vendors such as Millipore and Bethyl Laboratories) can be used for USP33 detection . These antibodies have been validated for multiple applications including western blotting, immunoprecipitation, immunofluorescence, immunohistochemistry with paraffin-embedded sections, and ELISA . When selecting an antibody, researchers should consider the specific application, species reactivity (human, mouse, etc.), and the particular epitope recognized by the antibody.

What experimental techniques can be used to detect USP33 in biological samples?

USP33 can be detected using several experimental techniques:

• Western Blotting (WB): This is commonly used to detect USP33 in cell lysates and tissue samples, allowing for protein quantification and expression level analysis .

• Immunoprecipitation (IP): This technique is valuable for studying protein-protein interactions involving USP33, such as its interaction with Robo1 or TGFBR2 .

• Immunofluorescence (IF): Useful for visualizing the subcellular localization of USP33 in fixed cells .

• Immunohistochemistry (IHC): Particularly with paraffin-embedded sections (IHCP), this method allows for detection of USP33 in tissue samples and is valuable for clinical specimens .

• ELISA: QuickTest ELISA kits are available for quantitative measurement of USP33 in various sample types including serum, plasma, cell culture supernatant, and cell or tissue lysates .

The choice of method depends on the specific research question, sample type, and required sensitivity and specificity.

How does USP33 interact with the Slit-Robo signaling pathway and what methods can elucidate this interaction?

USP33 has been identified as a Robo1-interacting protein through yeast two-hybrid screens using the Robo1 intracellular domain as bait . This interaction is significant in the Slit-Robo signaling pathway, which regulates cell migration, particularly in breast cancer cells .

To study this interaction, researchers can employ:

• Co-immunoprecipitation (Co-IP): This technique can confirm the interaction between endogenously expressed Robo1 and USP33. Experiments have shown that anti-USP33 antibody can co-immunoprecipitate Robo1 in MDA231 cells, indicating their interaction .

• Recombinant protein expression: Expressing tagged versions of Robo1 (e.g., HA-tagged) and USP33 (e.g., GFP-tagged) in mammalian cells like HEK293 allows for studying their interaction under various conditions, including Slit treatment .

• RNA interference: siRNAs targeting USP33 (e.g., siUSP33) can be used to knock down USP33 expression and examine the functional consequences on Slit-Robo signaling. Two different siRNAs specifically against USP33 have been shown to efficiently knock down USP33 expression in both HEK293 and MDA231 cells .

• Migration assays: The Dunn chamber chemotaxis assay can be used to assess the impact of USP33 knockdown on cell migration in response to chemoattractants like SDF1, with or without Slit treatment .

These methodologies can help elucidate how USP33 contributes to Slit-Robo signaling and its role in regulating cell migration in normal and cancer cells.

What is the role of USP33 in cancer progression and how can researchers investigate this aspect?

USP33 has been implicated in cancer progression, particularly in pancreatic cancer (PC). Research has found that USP33 is upregulated in PC samples and cells, and its high expression correlates with poor prognosis in patients . USP33 promotes the proliferation, migration, and invasion of PC cells through a positive feedback loop with the TGF-β signaling pathway .

Researchers can investigate USP33's role in cancer progression through:

• Expression analysis: Comparing USP33 expression levels between cancer and normal tissues using techniques like western blotting, immunohistochemistry, and qRT-PCR .

• Functional assays: Manipulating USP33 expression (overexpression or knockdown) in cancer cell lines to assess effects on:

  • Proliferation (using MTT/CCK8 assays, colony formation)

  • Migration and invasion (using transwell assays, wound healing assays)

  • Cell cycle progression (using flow cytometry)

  • Apoptosis (using Annexin V/PI staining)

• Mechanistic studies: Investigating the molecular mechanisms through which USP33 affects cancer progression:

  • Mass spectrometry and luciferase complementation assays to identify binding partners (e.g., TGFBR2)

  • Deubiquitination assays to assess USP33's enzymatic activity on specific targets

  • Signaling pathway analysis to determine USP33's impact on pathways like TGF-β signaling

• In vivo models: Using xenograft models to evaluate the impact of USP33 manipulation on tumor growth and metastasis.

These approaches can help elucidate USP33's role in cancer and potentially identify it as a prognostic marker or therapeutic target.

How is USP33 regulated at the post-translational level, and what techniques can be used to study its degradation?

USP33 is regulated at the post-translational level through degradation via the ubiquitin-proteasome system. A novel pathway involving the E3 ubiquitin ligase HERC2, the ATPase p97 (also known as VCP), and the adaptor complex Ufd1-Npl4 has been identified as critical for USP33 degradation .

To study USP33 degradation, researchers can employ:

• Protein stability assays: Using cycloheximide chase assays to track USP33 protein levels over time in the presence of protein synthesis inhibition.

• RNA interference: Knocking down components of the degradation machinery (e.g., p97, HERC2) to assess their impact on USP33 levels. Studies have shown that p97 depletion results in a 3.3-8 fold increase in USP33 levels, indicating its role in USP33 degradation .

• Ubiquitination assays: Using immunoprecipitation followed by ubiquitin western blotting to detect ubiquitinated forms of USP33.

• Proteasome inhibition: Treating cells with proteasome inhibitors (e.g., MG132) to determine if USP33 degradation is proteasome-dependent.

• Reconstitution experiments: Expressing RNAi-resistant USP33 constructs in USP33-depleted cells to validate specificity and perform structure-function analyses .

• Domain mapping: Creating deletion or point mutants to identify regions of USP33 that are important for its stability and degradation.

• Quantitative mass spectrometry: This technique has been used to identify proteins involved in USP33 regulation .

Understanding the mechanisms of USP33 degradation may provide insights into how its levels and functions are regulated in different cellular contexts.

What factors should be considered when selecting a USP33 antibody for specific applications?

When selecting a USP33 antibody for research, several factors should be considered:

• Application compatibility: Ensure the antibody has been validated for your specific application (WB, IP, IF, IHC, or ELISA). For example, the USP33 Antibody (1D7) has been validated for all these applications .

• Species reactivity: Confirm that the antibody recognizes USP33 from your species of interest. Some antibodies, like the 1D7 clone, specifically detect human USP33 .

• Isoform specificity: USP33 has three isoforms resulting from alternative splicing . Depending on your research question, you may need an antibody that recognizes all isoforms or one that is isoform-specific.

• Epitope location: Consider whether the epitope recognized by the antibody might be masked in certain experimental conditions or protein interactions.

• Antibody format: Determine whether you need a non-conjugated antibody or one conjugated to a reporter (e.g., HRP, fluorophore).

• Clone type: Decide between monoclonal (more specific, less batch variation) or polyclonal (often more sensitive, recognizes multiple epitopes) antibodies based on your experimental needs.

• Validation: Review published literature and manufacturer data showing validation of the antibody in applications similar to yours.

• Controls: Consider the availability of appropriate positive and negative controls for validating the antibody in your system.

Careful selection based on these criteria will help ensure successful detection of USP33 in your experiments.

How can USP33 antibodies be validated for specificity and sensitivity in various experimental systems?

Validating USP33 antibodies for specificity and sensitivity is crucial for reliable experimental results. Here are methodological approaches for antibody validation:

• Knockout/knockdown controls: Use USP33 knockout cell lines or siRNA-mediated knockdown samples as negative controls. Studies have shown efficient knockdown of USP33 using specific siRNAs (e.g., siUSP33 nos. 1 and 2) , reducing USP33 expression to approximately 20% of control levels.

• Overexpression controls: Express tagged versions of USP33 (e.g., FLAG-tagged or GFP-tagged) to serve as positive controls and to confirm antibody specificity.

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide to demonstrate that the antibody binding is specific to the target epitope.

• Cross-reactivity assessment: Test the antibody against related proteins, particularly USP20, which is closely related to USP33 , to confirm specificity.

• Multi-antibody approach: Use multiple antibodies targeting different epitopes of USP33. For example, compare results from monoclonal antibody 1D7 with those from polyclonal antibodies from Millipore or Bethyl Laboratories .

• Multiple detection methods: Validate findings using complementary techniques (e.g., confirming western blot results with immunofluorescence).

• Recombinant protein detection: Use purified recombinant USP33 protein at known concentrations to establish sensitivity limits and create standard curves, particularly for quantitative applications like ELISA .

• Reproducibility testing: Perform replicate experiments across different lots of antibody and sample preparations to ensure consistent results.

Proper validation ensures that the observed signals genuinely represent USP33 and not non-specific interactions or cross-reactivity with other proteins.

What are common challenges in USP33 detection and how can they be addressed?

Researchers may encounter several challenges when detecting USP33:

• Low endogenous expression: In some cell types, USP33 may be expressed at low levels, making detection difficult. This can be addressed by:

  • Optimizing protein extraction protocols to maximize yield

  • Using more sensitive detection methods (e.g., enhanced chemiluminescence for WB)

  • Increasing antibody concentration or incubation time

  • Enriching the target protein through immunoprecipitation before detection

• Isoform complexity: USP33 exists in three isoforms due to alternative splicing , which may complicate interpretation of results. Researchers should:

  • Be aware of which isoforms their antibody detects

  • Use appropriate molecular weight markers to identify specific isoforms

  • Consider using isoform-specific primers for RT-PCR validation

• Non-specific binding: This is particularly problematic in tissues with high background. Solutions include:

  • Optimizing blocking conditions (concentration, time, blocking agent)

  • Using more stringent washing protocols

  • Titrating antibody concentration to find the optimal signal-to-noise ratio

  • For IHC/IF, including antigen retrieval steps and optimizing fixation protocols

• Antibody batch variation: Different lots of the same antibody may show variation in performance. Researchers should:

  • Test new lots against previously validated lots

  • Maintain consistent experimental conditions

  • Include appropriate positive and negative controls with each experiment

• Post-translational modifications: USP33's function as a deubiquitinating enzyme means it interacts with the ubiquitin system and may itself be modified. Consider:

  • How sample preparation might affect these modifications

  • Whether certain modifications might mask antibody epitopes

  • Using phosphatase or deubiquitinase inhibitors in lysates if relevant

• Subcellular localization: USP33 is found in multiple cellular compartments including cytoplasm, nucleus, endoplasmic reticulum, Golgi, and centrosome . For accurate localization studies:

  • Use proper fractionation techniques

  • Employ co-localization with compartment-specific markers

  • Consider fixation methods that best preserve the relevant structures

Addressing these challenges through methodological optimization will improve the reliability of USP33 detection.

How can data from USP33 expression analyses be correctly interpreted in the context of cancer research?

Interpreting USP33 expression data in cancer research requires careful consideration of several factors:

• Expression level analysis: Elevated USP33 levels have been associated with poor prognosis in pancreatic cancer . When analyzing expression data:

  • Compare tumor samples with matched normal tissues

  • Correlate expression levels with clinical parameters (stage, grade, survival)

  • Consider both protein (using antibody-based methods) and mRNA expression

  • Use appropriate statistical analyses to determine significance

• Functional correlation: Link expression data with functional outcomes by:

  • Correlating USP33 levels with proliferation, migration, or invasion markers

  • Performing gain/loss-of-function studies to establish causality

  • Investigating downstream effects on signaling pathways (e.g., TGF-β signaling)

• Mechanistic interpretation: Consider USP33's known functions:

  • As a deubiquitinating enzyme, high USP33 expression may stabilize oncoproteins by preventing their degradation

  • USP33's interaction with specific pathways (e.g., Slit-Robo, TGF-β) may explain tissue-specific effects

  • Its regulation by HERC2/p97 may be disrupted in certain cancers

• Technical considerations:

  • Ensure antibody specificity through proper controls

  • Be aware of potential cross-reactivity with related proteins like USP20

  • Consider the detection method's limitations (sensitivity, dynamic range)

  • Account for heterogeneity within tumor samples

• Integration with other biomarkers:

  • Analyze USP33 in the context of other markers in the same pathway

  • Consider multi-marker panels for improved prognostic value

  • Investigate potential synergistic effects with other deregulated proteins

• Therapeutic implications:

  • Evaluate whether USP33 could serve as a therapeutic target

  • Consider how USP33 expression might affect response to existing therapies

  • Explore whether inhibiting USP33 or its interactions might have therapeutic potential

What protocols are recommended for quantitative measurement of USP33 using ELISA techniques?

For quantitative measurement of USP33 using ELISA techniques, the following protocol is recommended based on the QuickTest ELISA method :

• Sample preparation:

  • For serum or plasma: Centrifuge samples after collection to remove cellular components

  • For cell culture supernatant: Remove particulates by centrifugation

  • For cell/tissue lysates: Use appropriate lysis buffers with protease inhibitors

  • Dilute samples if necessary to fall within the standard curve range (0.156-10 ng/ml)

• Assay setup:

  • Prepare Cap/Det Ab working solution by diluting capture and detection antibodies

  • Add the Cap/Det Ab working solution to each well of the QuickTest plate

  • Add standards (for standard curve) and samples to appropriate wells

  • During this step, if USP33 is present in the sample, a capture antibody-USP33-biotin-detection antibody complex will form

• Incubation and washing:

  • Incubate the plate for the specified time (typically 120 minutes)

  • Wash thoroughly using wash buffer to remove unbound conjugates

  • Add HRP-Streptavidin to each well

  • Incubate for the specified time

  • Wash again to remove unbound HRP-Streptavidin

• Detection:

  • Add TMB substrate solution to each well

  • HRP will catalyze TMB to produce a blue color product

  • Add stop solution, which will turn the color from blue to yellow

  • Measure the absorbance at 450 nm using a microplate reader

• Data analysis:

  • Construct a standard curve using the absorbance values of the standards

  • Calculate the concentration of USP33 in samples using the standard curve

  • The concentration of USP33 is proportional to the OD450 value

• Quality control:

  • Include duplicate or triplicate wells for each sample and standard

  • Ensure the R² value of the standard curve is >0.98

  • Include positive and negative controls in each assay

The sensitivity of the assay is approximately 0.094 ng/ml, with a detection range of 0.156-10 ng/ml . This method provides a reliable quantitative measurement of USP33 in various biological samples.

How might USP33 antibodies be utilized in developing novel therapeutic approaches for cancer?

USP33 antibodies could contribute to novel therapeutic approaches for cancer in several ways:

• Target validation and mechanism studies:

  • USP33 antibodies are essential tools for validating USP33 as a therapeutic target in various cancers

  • They can help elucidate the mechanisms by which USP33 promotes cancer progression, particularly through the TGF-β signaling pathway in pancreatic cancer

  • By identifying USP33's protein interactions and substrates, antibodies can reveal potential points of intervention

• Diagnostic and prognostic applications:

  • Immunohistochemistry using USP33 antibodies could help stratify patients based on USP33 expression levels

  • Given that high USP33 expression correlates with poor prognosis in pancreatic cancer , antibody-based detection might identify patients who could benefit from USP33-targeted therapies

  • Multiplex immunostaining combining USP33 with other markers could improve diagnostic accuracy

• Therapeutic antibody development:

  • While direct therapeutic antibodies against USP33 would be challenging due to its intracellular location, antibody-drug conjugates (ADCs) could potentially be developed if USP33 has accessible extracellular domains or is abnormally exposed in cancer cells

  • Anti-USP33 antibodies might be engineered to deliver siRNAs or other therapeutic molecules into cells overexpressing USP33

• Monitoring treatment response:

  • USP33 antibodies could be used to monitor changes in USP33 expression or activity during treatment

  • This could help assess the efficacy of therapies targeting USP33 or related pathways

• Combination therapy strategies:

  • Understanding USP33's role in TGF-β signaling could inform combination approaches targeting both USP33 and other components of this pathway

  • USP33 antibodies would be valuable tools for studying such interactions and optimizing combination strategies

• Development of small molecule inhibitors:

  • While not direct therapeutic applications of antibodies themselves, USP33 antibodies are crucial for screening and validating small molecule inhibitors of USP33's deubiquitinating activity

  • Such inhibitors could potentially disrupt the USP33-mediated deubiquitination of TGFBR2, thereby inhibiting sustained TGF-β signaling in cancer cells

As research progresses, USP33 antibodies will continue to be essential tools for developing and validating novel therapeutic approaches targeting this important deubiquitinating enzyme in cancer.

What emerging technologies might enhance the specificity and sensitivity of USP33 detection in complex biological samples?

Several emerging technologies could enhance USP33 detection in complex biological samples:

• Proximity ligation assay (PLA):

  • This technique combines antibody technology with DNA amplification, allowing detection of protein-protein interactions or post-translational modifications

  • For USP33, PLA could enable visualization of its interactions with binding partners like Robo1 or TGFBR2 with single-molecule sensitivity

  • PLA could also detect USP33's deubiquitinating activity by monitoring changes in ubiquitination status of target proteins

• Mass cytometry (CyTOF):

  • Combining flow cytometry with mass spectrometry, CyTOF allows simultaneous detection of multiple proteins using metal-tagged antibodies

  • This could enable comprehensive profiling of USP33 expression alongside numerous signaling molecules in heterogeneous cell populations

  • CyTOF would be particularly valuable for analyzing USP33 in complex samples like tumor biopsies

• Super-resolution microscopy:

  • Techniques like STORM, PALM, or STED microscopy overcome the diffraction limit, providing nanoscale resolution

  • These approaches could precisely localize USP33 within subcellular compartments (cytoplasm, nucleus, endoplasmic reticulum, Golgi, centrosome)

  • When combined with specific antibodies, super-resolution microscopy could reveal previously undetectable aspects of USP33 localization and function

• Antibody engineering:

  • Development of recombinant antibody fragments (Fab, scFv) with enhanced specificity for USP33

  • Nanobodies (single-domain antibodies) derived from camelid antibodies could offer improved access to sterically hindered epitopes

  • Bispecific antibodies targeting USP33 and one of its interaction partners could improve specificity for particular USP33 complexes

• Quantitative multiplexed immunofluorescence:

  • Cyclic immunofluorescence or multispectral imaging allows detection of multiple targets in the same sample

  • This would enable simultaneous visualization of USP33, its substrates, and interacting proteins in tissue sections

  • Quantitative analysis could provide spatial information about USP33 function in different cellular contexts

• Digital ELISA platforms:

  • Single-molecule array (Simoa) technology can detect proteins at femtomolar concentrations

  • This could enable detection of extremely low levels of USP33 in biological fluids like plasma or cerebrospinal fluid

  • Such sensitivity could reveal previously undetectable changes in USP33 levels in various physiological or pathological conditions

• CRISPR-based tagging:

  • Endogenous tagging of USP33 using CRISPR/Cas9 followed by detection with anti-tag antibodies

  • This approach avoids potential artifacts associated with overexpression systems

  • When combined with live-cell imaging, it could provide dynamic information about USP33 localization and interactions

These technologies, when combined with high-quality USP33 antibodies, have the potential to significantly advance our understanding of USP33 biology in health and disease.

How might research on USP33 and its antibodies inform understanding of other deubiquitinating enzymes?

Research on USP33 and its antibodies provides valuable insights that can be applied to understanding other deubiquitinating enzymes (DUBs) in several ways:

• Methodological advances:

  • Techniques optimized for USP33 detection, including antibody validation strategies, can be adapted for other DUBs

  • Successful approaches for studying USP33's enzymatic activity, substrate specificity, and protein interactions provide templates for investigating other DUBs

  • The sandwich ELISA methodology developed for USP33 could be adapted for quantitative measurement of other DUBs

• Regulatory mechanisms:

  • The discovery that USP33 is degraded through a pathway involving HERC2 and p97 suggests that similar mechanisms might regulate other DUBs

  • Understanding how USP33 itself is regulated post-translationally provides insights into potential regulatory mechanisms for the broader DUB family

  • The finding that USP33 is part of a feedback loop with TGF-β signaling highlights how DUBs can both regulate and be regulated by signaling pathways

• Functional contexts:

  • USP33's role in Slit-Robo signaling and TGF-β signaling suggests that other DUBs might similarly function in specific signaling pathways

  • The identification of USP33 as a cancer-promoting factor in pancreatic cancer encourages investigation of other DUBs as potential oncogenes or tumor suppressors

  • Understanding how USP33 stabilizes specific targets like TGFBR2 provides a conceptual framework for studying substrate specificity among DUBs

• Therapeutic applications:

  • Approaches being developed to target USP33 in cancer could inform strategies for targeting other DUBs with oncogenic functions

  • The use of antibodies to validate USP33 as a therapeutic target establishes a precedent for similar validation of other DUBs

  • Cross-reactivity studies between USP33 and closely related DUBs (like USP20) highlight the importance of specificity in DUB-targeted therapeutics

• Evolutionary and structural insights:

  • Comparative studies of USP33 across species can illuminate conserved functions of the USP family

  • Structural analyses of USP33, facilitated by specific antibodies, could reveal common structural features shared with other DUBs

  • Understanding the basis for USP33's substrate specificity might explain how different DUBs recognize their specific targets

By serving as a model DUB, research on USP33 contributes to the broader understanding of this important enzyme family, potentially accelerating discovery across the field of ubiquitin research.

What is the potential impact of USP33 research on broader areas of cell biology and disease mechanisms?

The study of USP33 and the development of specific antibodies for its detection have far-reaching implications for multiple areas of cell biology and disease research:

• Cancer biology:

  • USP33's role in promoting pancreatic cancer through TGF-β signaling suggests it may be involved in other malignancies

  • Understanding how USP33 contributes to cancer proliferation and metastasis may reveal common mechanisms applicable to multiple cancer types

  • USP33's interaction with Robo1 in the context of breast cancer cell migration highlights its potential role in metastatic processes

• Signal transduction:

  • USP33's involvement in both Slit-Robo and TGF-β signaling positions it as an important regulator of multiple pathways

  • The finding that USP33 deubiquitinates TGFBR2 to prevent its lysosomal degradation illustrates a general mechanism by which DUBs can regulate receptor abundance and signaling duration

  • This research contributes to understanding how deubiquitination counterbalances ubiquitination in signaling pathway regulation

• Protein quality control:

  • The discovery that USP33 is regulated by HERC2 and p97 provides insights into how the ubiquitin-proteasome system regulates its own components

  • This work contributes to understanding of protein homeostasis mechanisms, which are critical in preventing diseases associated with protein misfolding or aggregation

  • The study of USP33 degradation exemplifies how tight regulation of deubiquitinating enzymes is necessary for cellular function

• Developmental biology:

  • USP33's role in Slit-Robo signaling , which is important for neuronal guidance, suggests potential functions in development

  • Understanding USP33's contribution to cell migration may illuminate developmental processes requiring precise cellular movements

  • The regulation of receptor levels by USP33 may have implications for morphogen gradient formation during development

• Neuroscience:

  • Given the importance of Slit-Robo signaling in neuronal guidance, USP33's role in this pathway suggests potential functions in neural development or regeneration

  • USP33 may be involved in neuronal migration, axon guidance, or synapse formation

  • Perturbations in USP33 function could potentially contribute to neurodevelopmental disorders

• Inflammation and immunity:

  • The ubiquitin system plays crucial roles in immune signaling, suggesting USP33 might regulate immune responses

  • The methodologies developed for studying USP33 could be applied to investigate DUBs involved in inflammatory pathways

  • USP33 might be involved in regulating the stability of immune receptors or signaling components

• Therapeutic development:

  • Understanding USP33's structure, function, and regulation provides a foundation for developing inhibitors or modulators of its activity

  • Such therapeutics could have applications in cancer and potentially other diseases where USP33 plays a role

  • The positive feedback loop between USP33 and TGF-β signaling identifies a potential point of intervention for disrupting pathological signaling